Drugs / 99mTc-Fucoidan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03422055 | Feb → May 2018 | — | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99mTc-Fucoidan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03422055 ↗ |
| Known as | 99mTechnetium-labelled fucoidan | “We showed that 99mTechnetium-labelled fucoidan was able to target P-selectin expressed by activated platelets in vitro in humans and in vivo in a model of abdominal aortic...” NCT03422055 ↗ |
| Modality | Diagnostic / imaging agent | “99mTc-fucoidan SPECT/CT imaging.” PMID 39562382 ↗ Nov 2024 |
| Route | Intravenous | “intravenous administration of 99mTc-Fucoidan” NCT03422055 ↗ |